Jump to content

Panacea Biotec

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dharam00000007 (talk | contribs) at 18:16, 4 July 2013 (Addition of more Information). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Panacea Biotec
Company typePublic
IndustryPharmaceutical industry
Founded1984
HeadquartersNew Delhi, India
Key people
Soshil Kumar (Executive Chairman of the Board, Ravinder Jain (Managing Director), Dr. Rajesh Jain (Joint Managing Director), Sandeep Jain (Joint Managing Director)
ProductsPharmaceuticals, generic drugs, vaccine
Websitewww.panacea-biotec.com

Panacea Drugs Pvt. Ltd. was set up in the year 1984 and got listed in 1995 as Panacea Biotec Ltd. Panacea Biotec is an Indian research based pharmaceutical and health management company involved in research, manufacturing, and marketing of pharmaceutical formulations, vaccines, and natural products.[1] It is one of the three largest biotech companies in India.[2] In August 2011 several of its hepatitis vaccines were removed from the list of prequalified vaccines by the World Health Organization[3] because of quality management issues, but the issues were resolved by early 2012.[4]

Panacea Biotec has 5 research centres across India that specialize in the fields of pharmaceuticals, biotechnology, natural products and biopharmaceutics.

History

Panacea Biotec is the largest Vaccine manufacturing Company in India and is well acknowledged by the UN Health Agencies in partnering the Polio eradication initiative with supplies of millions of doses of WHO Pre-qualified Polio vaccine. As a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV) Panacea Biotec has introduced the next generation Inactivated Polio vaccine (eIPV) vide a collaboration with the Netherland Vaccine Institute. This vaccine has found extensive usage in India for more than 3 years now and is registered in Bangladesh. IPV is also in advanced stage of registration in 10 countries word wide with the target of being in more than 30 countries in a couple of years and has been put up for WHO prequalification which is expected soon.[5]

Panacea Biotec timeline:

  • 1984-Panacea Drug (P) Ltd. was formed
  • 1988-Established a plant for vaccines production at New Delhi, under the name of Radicura Pharma
  • 1989-Pharmaceutical formulations plant at New Delhi,under the name of Panacea Drug P Ltd.
  • 1993-Merger of Panacea Drugs (P) Ltd. & Radicura Pharma to form Panacea Biotec Ltd.
  • 1995-IPO of Equity Shares of Rs.180 Million
  • 1995-State -of the- art Drug Delivery R&D centre at Lalru
  • 1997-First Product Patent in Several Countries
  • 2001-R&D tie up with European MNC
  • 2002-In-licensing Agreement with Biotechnology Consortium of India for Development & Commercialization of Anthrax Vaccine
  • 2002-Commissioning of Recombinant Vaccine Production Plant
  • 2004-In-licensing agreement with National Institute of Immunology, New Delhi, for Japanese Encephalitis Candidate Vaccine
  • 2004-Marketing Joint Venture with Chiron (now Novartis) Vaccines, UK
  • 2004-Collaboration with Cambridge Bio-stability, UK, for Thermo Stable Vaccines
  • 2005-In-licensing agreement with National Institute of Health, USA for Hair Growth Hormone
  • 2006-WHO cGMP complaint ultra modern Pharmaceuticals formulation facility at Baddi, Himachal Pradesh.

Landmark collaborations with The Netherlands Vaccine Institute (The Nederlands Vaccin Instituut (NVI)) for manufacture & marketing of finished Inactivated Polio Vaccine (IPV) and a number of IPV based combination vaccines in India and across the globe. Collaboration with PT.Bio Farma to manufacture & market Measles Vaccine. Inauguration of Biopharmaceutical R&D Centre at New Delhi Pre-Qualification Certification from WHO for Supply of Recombinant Hepatitis-B Vaccine to UN Agencies. Collaboration with National Research Development Corporation (NRDC) for technology transfer of Foot and Mouth Vaccine.

  • 2007-Vaccine Formulation Plant at Baddi

Research Agreement with Punjab University to develop New Chemical Entities for Psychiatric Disorders

  • 2008-Foray into Healthcare Delivery –collaboration to set-up 220 bed multi super-specialty hospital in NCR

WHO prequalification for fully liquid innovative combination Pentavalent vaccine, EasyFive* against five deadly infectious diseases (DTwP+ Hep B+ Hib) of early childhood. Granted a patent from US Patent & Trademark Office for our product Thank GodTM (Euphorbia Prostrata) for effective management of hemorrhoids & piles (Patent No. 7,371,412 B2)[6]

References

  1. ^ "New vaccines to lift sales at Panacea Biotec". International Herald Tribune. 18 August 2005. Retrieved 2009-03-05.
  2. ^ Risky Business, Express Pharma, December 2, 2011
  3. ^ "Bharat Biotech gets WHO blow over Hep-B vaccine", The Times of India, December 15, 2011
  4. ^ equitybulls.com
  5. ^ [1]
  6. ^ [2]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Panacea_Biotec&oldid=562864586"